On September 22, 2026, a delegation from Shenzhen Bao'an District People's Hospital, led by President Deng Ying, Vice President Li Hongtao, and Vice President Chen Jihong, along with experts and postdoctoral teams from departments including the Science and Education Department, the Industry Conduct and Ethics Office, the Endocrinology Department, the Pediatrics Department, the Nephrology Department, the Respiratory Department, the Hematology Department, the Orthopedic Trauma Department, and the Medical Aesthetic Surgery Department, visited the Shenzhen-Hong Kong Cell Valley for an in-depth cooperation research and exchange. Shi Yuanyuan, Chairman and General Manager of the Cell Valley Group; Sun Rui, Head of Marketing; Fu Yuchen, Director of the International Medical Center; and Zhu Wenxiang, Senior R&D Scientist, jointly received the delegation.

During the visit, the delegation from Bao'an District People's Hospital toured the Shenzhen-Hong Kong Cell Valley smart exhibition hall, gaining a detailed understanding of the platform's technology layout, industrialization development, and clinical translation progress, and experiencing firsthand the Cell Valley Group's innovative development achievements.

During the symposium, the two parties engaged in in-depth discussions on the clinical application and translation of cell therapy technologies. Professor Shi Yuanyuan extended a warm welcome to the delegation from Bao'an District People's Hospital and systematically introduced the Cell Valley Group's overall strategic layout in recent years around the three dimensions of "technology platform + clinical translation + regional services." Drawing on the Group's clinical cooperation practices with multiple top-tier tertiary hospitals, he highlighted the Cell Valley Group's accumulation and advantages in the field of emerging biomedical technologies, and provided a detailed presentation of the platform's comprehensive service capabilities in technology R&D, process quality control, and project compliance management. He expressed hope that both parties would take this exchange as an opportunity to deepen cooperation in clinical research and technology translation, jointly promoting the clinical implementation of more emerging biomedical technologies so that cutting-edge achievements can truly benefit patients.

President Deng Ying fully affirmed the Cell Valley Group's clinical application and translation achievements. She stated that Bao'an District People's Hospital has a comprehensive range of clinical disciplines and abundant case resources. The hospital will combine the clinical realities of departments including nephrology, pediatrics, respiratory diseases, hematological diseases, orthopedic trauma, and medical aesthetic surgery to identify actual needs and researchable directions in diagnosis and treatment, and engage in more detailed alignment with the Cell Valley Group. She expressed the hope to leverage the hospital's clinical resources and combine them with the Cell Valley Group's industrial R&D platform to jointly explore feasible pathways for serving clinical needs with cutting-edge technologies.

This research and cooperation laid a solid foundation for the two parties to subsequently establish cooperation in research collaboration and clinical translation. Going forward, the Cell Valley Group will promote cell therapy innovative technologies to better serve clinical needs and contribute to the high-quality development of the regional biopharmaceutical and healthcare sectors.